AdAlta, the Australian biotech pioneering a next generation biologic called an i-body, is pleased to announce that its CEO Sam Cobb will speak on two panels at the largest life science conference in Australia, AusBiotech 2018 (October 31 – November 2).
Ms Cobb will draw on her experience as one of just 13 percent of female CEOs in the Australian life sciences sector[1], for the panel discussion: Gender diversity in Australian biotech, November 1, 9.45am.
Later that day, Ms Cobb will highlight the potential of AdAlta’s i-body platform to target one of the most therapeutically relevant yet to difficult to access class of receptors, G coupled Protein Receptors, as part of the panel: From bench to bedside: GPCR drug discovery, November 1, 11am.
“AdAlta’s i-body is a world-first in next generation biologics; it is a human protein engineered with a very long loop that can access deep grooves and cavities, with great target specificity,” Ms Cobb explained.
“AdAlta now has a substantial body of data to support the therapeutic potential of the i-body.
“We’re developing our i-body therapy, AD-214, with a focus on the lung disease Idiopathic Pulmonary Fibrosis (IPF). AD-214 binds and exerts its anti-inflammatory and anti-fibrotic effect on a type of GPCR chemokine receptor called CXCR4, which is a novel disease target pathway for IPF not currently addressed by approved drugs or those drug candidates in the clinic.
“We are excited to be progressing AD-214 to the clinic, and we expect to undertake our first human trials in early 2020.”
AusBiotech 2018 will be held at the Brisbane Convention and Exhibition Centre, Southbank. More details: http://ausbiotechnc.org/program
[1] Roberts S. 22 December 2017, Australia’s growing support for women in life sciences, Retrieved from http://www.ndfresearch.com/womeninlifesciences.html [Accessed 15 October 2018]